Lymphocyte Count Correlated to Comorbid Diabetes and COVID-19
By LabMedica International staff writers Posted on 03 Sep 2020 |
Image: A blood film with a normal mature lymphocyte with a single large nucleus is seen on the left, compared to two segmented neutrophils on the right with multiple nuclear lobes. The lymphocytes are decreased in comorbid diabetes and COVID-19 patients (Photo courtesy of Ed Reschke).
The coronavirus disease (COVID-19) that erupted in China since December 2019 and has gradually spread throughout the world. At present, it has caused tens of thousands of deaths, and the efficacy of certain antiviral drugs is still under review.
Patients with diabetes are more prone to disease progression than those without diabetes; however the mechanism is not yet clear. Depending on the region, 20% to 50% of patients affected by the COVID-19 pandemic had diabetes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a reduction in the lymphocyte count of COVID-19 patients.
Medical scientists at the Nanjing Medical University (Wuxi, China) included in a study 63 adult patients with COVID-19 who were admitted to the hospital from January 29 to March 15, 2020. Patients were classified as having diabetes (n=16) or not having diabetes (n=47). Lymphocytes measured and recorded at admission and during treatment were analyzed and compared between groups. Other outcomes assessed in this study included the number of hospitalization days, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid positive days, and minimal lymphocyte count.
Data pertaining to gender, age, type 2 diabetes mellitus (T2DM) status, body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were obtained at the time of admission. Data on alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), and fasting glucose were obtained the next morning after admission. White blood cell count (WBC), C-reactive protein (CRP) and Lymphocytes were measured at admission and during treatment.
The scientists reported that at time of admission, patients with diabetes had a significantly higher maximal C-reactive protein (91.75 mg/L versus 17.0 mg/L) and fasting glucose (8.81 ± 2.42 mmol/L [158.74 ± 43.6 mg/dL] versus 6.01 ± 1.89 mmol/L [108.3 ± 34.1 mg/dL]). A lower minimal lymphocyte count was observed in patients with diabetes versus without diabetes (0.67 ± 0.36 ×109/L versus 1.30 ± 0.54×109/L, respectively). Additionally, the investigators found that the minimal lymphocyte count occurred significantly earlier in patients with diabetes compared with the non-diabetes group (2.68 ± 2.33 days versus 5.29 ± 4.95 days, respectively). Patients with diabetes and COVID-19 also had longer hospital stays (20.44 ± 5.24 days versus 17.11 ± 4.78 days). A negative correlation was found between the minimal lymphocyte count and both hospital days and SARS-CoV-2 nucleic acid positive days.
The authors concluded that COVID-19 patients with T2DM experience a faster decline in lymphocyte count, have lower lymphocyte count, and longer hospital stay than non-diabetic patients. The lower the lymphocyte count, the longer the hospitalization time and viral nucleic acid positive days. The study was published on August 1, 2020 in the journal Diabetes Research and Clinical Practice.
Related Links:
Nanjing Medical University
Patients with diabetes are more prone to disease progression than those without diabetes; however the mechanism is not yet clear. Depending on the region, 20% to 50% of patients affected by the COVID-19 pandemic had diabetes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a reduction in the lymphocyte count of COVID-19 patients.
Medical scientists at the Nanjing Medical University (Wuxi, China) included in a study 63 adult patients with COVID-19 who were admitted to the hospital from January 29 to March 15, 2020. Patients were classified as having diabetes (n=16) or not having diabetes (n=47). Lymphocytes measured and recorded at admission and during treatment were analyzed and compared between groups. Other outcomes assessed in this study included the number of hospitalization days, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid positive days, and minimal lymphocyte count.
Data pertaining to gender, age, type 2 diabetes mellitus (T2DM) status, body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were obtained at the time of admission. Data on alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), and fasting glucose were obtained the next morning after admission. White blood cell count (WBC), C-reactive protein (CRP) and Lymphocytes were measured at admission and during treatment.
The scientists reported that at time of admission, patients with diabetes had a significantly higher maximal C-reactive protein (91.75 mg/L versus 17.0 mg/L) and fasting glucose (8.81 ± 2.42 mmol/L [158.74 ± 43.6 mg/dL] versus 6.01 ± 1.89 mmol/L [108.3 ± 34.1 mg/dL]). A lower minimal lymphocyte count was observed in patients with diabetes versus without diabetes (0.67 ± 0.36 ×109/L versus 1.30 ± 0.54×109/L, respectively). Additionally, the investigators found that the minimal lymphocyte count occurred significantly earlier in patients with diabetes compared with the non-diabetes group (2.68 ± 2.33 days versus 5.29 ± 4.95 days, respectively). Patients with diabetes and COVID-19 also had longer hospital stays (20.44 ± 5.24 days versus 17.11 ± 4.78 days). A negative correlation was found between the minimal lymphocyte count and both hospital days and SARS-CoV-2 nucleic acid positive days.
The authors concluded that COVID-19 patients with T2DM experience a faster decline in lymphocyte count, have lower lymphocyte count, and longer hospital stay than non-diabetic patients. The lower the lymphocyte count, the longer the hospitalization time and viral nucleic acid positive days. The study was published on August 1, 2020 in the journal Diabetes Research and Clinical Practice.
Related Links:
Nanjing Medical University
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines